ATA1972000A - Rekombinant hergestelltes menschliches intestinales npt2b-polypeptid - Google Patents

Rekombinant hergestelltes menschliches intestinales npt2b-polypeptid

Info

Publication number
ATA1972000A
ATA1972000A AT0019700A AT1972000A ATA1972000A AT A1972000 A ATA1972000 A AT A1972000A AT 0019700 A AT0019700 A AT 0019700A AT 1972000 A AT1972000 A AT 1972000A AT A1972000 A ATA1972000 A AT A1972000A
Authority
AT
Austria
Prior art keywords
recombinantly made
intestinal npt2b
polypeptide
npt2b polypeptide
made intestinal
Prior art date
Application number
AT0019700A
Other languages
English (en)
Other versions
AT411759B (de
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Priority to AT15352001A priority Critical patent/AT412514B/de
Publication of ATA1972000A publication Critical patent/ATA1972000A/de
Application granted granted Critical
Publication of AT411759B publication Critical patent/AT411759B/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT0019700A 1999-02-09 2000-02-08 Rekombinant hergestelltes menschliches intestinales npt2b-polypeptid AT411759B (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AT15352001A AT412514B (de) 1999-02-09 2001-09-27 Verfahren zum screenen von npt2b-modulierenden mitteln

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11932199P 1999-02-09 1999-02-09

Publications (2)

Publication Number Publication Date
ATA1972000A true ATA1972000A (de) 2003-10-15
AT411759B AT411759B (de) 2004-05-25

Family

ID=22383760

Family Applications (1)

Application Number Title Priority Date Filing Date
AT0019700A AT411759B (de) 1999-02-09 2000-02-08 Rekombinant hergestelltes menschliches intestinales npt2b-polypeptid

Country Status (14)

Country Link
US (3) US6380374B1 (de)
JP (2) JP2000245488A (de)
AT (1) AT411759B (de)
AU (1) AU741170B2 (de)
BE (1) BE1014389A5 (de)
CA (1) CA2296178C (de)
CH (1) CH694588A5 (de)
DE (1) DE10004815B4 (de)
FR (1) FR2791348B1 (de)
GB (1) GB2348645A (de)
IE (1) IE20000117A1 (de)
IT (1) ITMI20000200A1 (de)
NL (1) NL1014331C2 (de)
SE (1) SE523043C2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1409549A4 (de) * 2001-06-20 2007-10-24 Genentech Inc Zusammensetzungen und verfahren für die diagnose und behandlung von tumoren
EP2351765A3 (de) * 2001-07-10 2012-02-22 Lakewood-Amedex, Inc Oligonukleotidhaltige pharmakologische zusammensetzungen und deren verwendung
US20050004348A1 (en) * 2002-12-23 2005-01-06 Miyamoto Ken-Ichi Novel type II Na/Pi cotransporters and type II Na/Pi cotransporter expression regulatory factors
EP2076286B1 (de) * 2006-10-25 2016-03-09 Wisconsin Alumni Research Foundation Verfahren zur verminderung der absorption von phosphat mit hilfe eines anti-npt2b antikörper
CA2667613A1 (en) * 2006-10-26 2008-06-05 Wisconsin Alumni Research Foundation Methods for reducing phosphate absorption
TWI507524B (zh) * 2009-11-30 2015-11-11 建南德克公司 診斷及治療腫瘤之組合物及方法
BR112018068461A2 (pt) 2016-03-15 2019-01-22 Mersana Therapeutics Inc conjugado, composição farmacêutica, métodos para preparação de um conjugado e para alívio de um sintoma de um câncer.
EP3685166A2 (de) 2017-09-20 2020-07-29 Mersana Therapeutics, Inc. Zusammensetzungen und verfahren zur vorhersage des ansprechens auf eine napi2b-gerichtete therapie
JP2021534188A (ja) 2018-08-17 2021-12-09 メルサナ セラピューティクス インコーポレイテッド ＮａＰｉ２ｂに標的指向されたポリマー抗体−薬物コンジュゲートおよびその使用方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985604A (en) 1997-02-24 1999-11-16 Incyte Pharmaceuticals, Inc. Human sodium-dependent phosphate cotransporter
US6319688B1 (en) * 1997-04-28 2001-11-20 Smithkline Beecham Corporation Polynucleotide encoding human sodium dependent phosphate transporter (IPT-1)

Also Published As

Publication number Publication date
SE0000375L (sv) 2000-08-10
SE0000375D0 (sv) 2000-02-07
CH694588A5 (de) 2005-04-15
US7368530B2 (en) 2008-05-06
CA2296178C (en) 2004-05-04
GB2348645A (en) 2000-10-11
BE1014389A5 (fr) 2003-10-07
GB0002665D0 (en) 2000-03-29
AU1497900A (en) 2000-08-31
JP2000245488A (ja) 2000-09-12
ITMI20000200A1 (it) 2001-08-08
US6380374B1 (en) 2002-04-30
US7803562B2 (en) 2010-09-28
DE10004815A1 (de) 2000-10-12
NL1014331C2 (nl) 2003-06-03
IE20000117A1 (en) 2000-09-06
AU741170B2 (en) 2001-11-22
ITMI20000200A0 (it) 2000-02-08
FR2791348A1 (fr) 2000-09-29
SE523043C2 (sv) 2004-03-23
AT411759B (de) 2004-05-25
DE10004815B4 (de) 2010-01-21
US20090170122A1 (en) 2009-07-02
JP2003325189A (ja) 2003-11-18
NL1014331A1 (nl) 2000-08-10
CA2296178A1 (en) 2000-08-09
FR2791348B1 (fr) 2007-10-05
US20020156266A1 (en) 2002-10-24

Similar Documents

Publication Publication Date Title
NO2010013I1 (no) Rekombinant FSH-CTP
NO982097L (no) Peptider
NO982098D0 (no) Peptider
DE69920011D1 (de) Rekombinanter venezolanische-equine-pferdeenzephalitis-virusimpstoff
DK0869075T3 (da) Udleveringstætning
DE69834429D1 (de) Antimikrobielle struktur
IS4974A (is) Lyfjasamsetning á þrýstingsúðaformi
DE69731238D1 (de) Aufblasbarer hemostat
DK0955058T3 (da) Lactoferrintabletter
PT1056448E (pt) Combinacoes farmaceuticas com tramadol
DE59800089D1 (de) Laryngoskop
DE69933647D1 (de) Rekombinante lysophosphatidsäure - phosphatase.
DE50010075D1 (de) Gleitringdichtung
EP1197556A4 (de) NüTZLICHE POLYPEPTIDE
FR2791348B1 (fr) POLYPEPTIDE Npt2B
ATE295417T1 (de) Angiostatin-bindendes protein
EP1359932A4 (de) Tip39 polypeptide
NO20004167L (no) Kaspase-8 interagerende proteiner
ATE381618T1 (de) Polypeptidhormon phosphatonin
EP1159288A4 (de) Alpha-conotoxin-peptide
DE50010794D1 (de) Gleitringdichtung
NO20005547D0 (no) Myelinbasiske proteinpeptider og anvendelser derav
NO20013933D0 (no) Peptider
NO20012283D0 (no) Koblede peptider
DK1189600T3 (da) GRF-holdige lyofiliserede farmaceutiske præparater

Legal Events

Date Code Title Description
MM01 Lapse because of not paying annual fees

Effective date: 20181015